Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.44 USD
Change Today +0.01 / 2.33%
Volume 1.3M
CYTX On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/14 - $2.21
52 Week Low
11/12/14 - $0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

78 Employees
Last Reported Date: 03/16/15
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $437.4K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $79.1K
President of Asia Pacific
Total Annual Compensation: $367.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics Announces U.S. FDA Conditional IDE Approval for Clinical Trial of Technology to Treat Female and Early Male Pattern Baldness

Cytori Therapeutics announced that Kerastem Technologies has received conditional approval from the U.S. Food and Drug Administration's (FDA) Investigational Device Exemption (IDE) to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness (androgenic alopecia). Kerastem Technologies is a wholly owned subsidiary of Bimini Technologies, which acquired the global and exclusive rights to commercialise Cytori Celution Technology for alopecia and hair related indications from Cytori in 2013. The company stated that the phase II study, called the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the U.S. FDA IDE submission. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centres within the US. The primary endpoint of STYLE trial is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density.

Cytori Therapeutics, Inc. Appoints Jeremy Hayden as VP of Business Development and General Counsel

Cytori Therapeutics, Inc. announced that Mr. Jeremy Hayden has been appointed as General Counsel and VP of Business Development. In addition to extensive legal experience in the life sciences industry, Mr. Hayden also has specific expertise in business development, with a lead role in structuring and negotiation of equity and debt financings, mergers and acquisitions, partnerships and collaborations, and inbound and outbound licensing arrangements. Mr. Hayden joins Cytori from Volcano Corporation, where he served as Assistant General Counsel and, among other responsibilities, served as legal business partner to Volcano’s business units and supported Volcano’s SEC and M&A activities, including Volcano’s merger with Royal Philips. Prior to his tenure at Volcano, Mr. Hayden was counsel at several legal firms, including McKenna Long & Aldridge, LLP and Mintz Levin Cohn Ferris Glovsky & Popeo, P.C., during which he advised public and private clients on a broad variety of transactions, including strategic growth, equity and debt investments and acquisitions.

Cytori Therapeutics, Inc. Announces Executive Changes

On June 30, 2015, Cytori Therapeutics, Inc. announced that John Townsend will resign his position as chief accounting officer. Mr. Townsend will continue until August 15, 2015 in order to assist the company in the transition of his responsibilities. Tiago Gir o, the company's vice president of finance and chief financial officer, will serve in the interim as principal accounting officer until the board of directors of the company appoints a successor.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $0.44 USD +0.01

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.05 USD -0.02
Caladrius Biosciences Inc $1.65 USD -0.08
International Stem Cell Corp $3.60 USD -0.80
Nuo Therapeutics Inc $0.20 USD +0.0012
StemCells Inc $0.41 USD +0.0052
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at